{"filing":{"accession_number":"0001193125-26-343446","cik":"0001400118","ticker":"SGMT","company_name":"Sagimet Biosciences Inc.","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"d36435d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1400118/000119312526343446/d36435d8k.htm"},"events":[{"id":26877,"run_id":24445,"accession_number":"0001193125-26-343446","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.94,"summary":"Sagimet disclosed Q2 2026 financial results via press release (Exhibit 99.1), reporting a net loss of $13.953 million for the quarter and $24.6 million for the six-month period, with a cash position of $257.6 million, along with corporate updates on clinical trial progress and equity financing.","company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28164,"accession_number":"0001193125-26-343446","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.02 discloses Sagimet's financial results for the quarter ended June 30, 2026, with a press release furnished as Exhibit 99.1. The filing reports Q2 2026 net loss of $13.953 million, cash position of $257.6 million, and R\u0026D/G\u0026A expenses, along with corporate updates on clinical trial progress and equity financing. This is a standard earnings release disclosure material to investors assessing the company's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:36:49.455498+00:00","company_name":"","ticker":null,"filing_date":""},{"id":28165,"accession_number":"0001193125-26-343446","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 7.01 disclosure references an updated slide presentation (Exhibit 99.2) for investor meetings, but the substantive content furnished includes Exhibit 99.1, which is a formal earnings release reporting Q2 2026 financial results (net loss of $13.95M for Q2, $24.6M for six months), cash position of $257.6M, and corporate updates on clinical trial progress. The earnings release is the material disclosure being made, even though technically filed under Item 7.01 (Regulation FD Disclosure) rather than Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:36:49.455498+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28164,"accession_number":"0001193125-26-343446","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.02 discloses Sagimet's financial results for the quarter ended June 30, 2026, with a press release furnished as Exhibit 99.1. The filing reports Q2 2026 net loss of $13.953 million, cash position of $257.6 million, and R\u0026D/G\u0026A expenses, along with corporate updates on clinical trial progress and equity financing. This is a standard earnings release disclosure material to investors assessing the company's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:36:49.455498+00:00","company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","filing_date":"2026-08-11"},{"id":28165,"accession_number":"0001193125-26-343446","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 7.01 disclosure references an updated slide presentation (Exhibit 99.2) for investor meetings, but the substantive content furnished includes Exhibit 99.1, which is a formal earnings release reporting Q2 2026 financial results (net loss of $13.95M for Q2, $24.6M for six months), cash position of $257.6M, and corporate updates on clinical trial progress. The earnings release is the material disclosure being made, even though technically filed under Item 7.01 (Regulation FD Disclosure) rather than Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:36:49.455498+00:00","company_name":"Sagimet Biosciences Inc.","ticker":"SGMT","filing_date":"2026-08-11"}]}